For its third fiscal quarter (ending September 30), Eli Lilly and Co (NYSE: LLY) has reported a -104% decline in E.P.S. from $1.61 a year ago to $-0.06 in the current quarter. This performance was $-0.93 short of the consensus estimate of $0.87. E.P.S. were $5.53 for the latest four quarters through September 30 versus $6.69 for the same period a year ago — a decline of -17%.
Recent Price Action
On 11/2/23, Eli Lilly and Co (NYSE: LLY) stock enjoyed a large increase of 4.7%, closing at $580.29. The stock has declined -1.1% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
LLY’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Eli Lilly has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Eli Lilly has a poor Appreciation Score of 19 but a very high Power Rating of 93, and the Neutral Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment